EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert maintains a Buy rating on Citius Pharma (NASDAQ:CTXR) with a $6 price target.
August 19, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert maintains a Buy rating on Citius Pharma with a $6 price target.
The reaffirmation of a Buy rating and a $6 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100